Cogent Biosciences signs 5-year supply deal with Hovione for bezuclastinib manufacturing

Cogent Biosciences, Inc.

Agreement with Hovione FarmaCiencia S.A. covers bezuclastinib spray-dried dispersion and tablets.
Initial 5-year term with automatic 2-year renewals; minimum purchase percentages decrease over time.
Quarterly forecasts; near-term portion binding, balance non-binding good-faith estimates.
Termination rights include uncured breach, prolonged force majeure, insolvency, regulatory developments.
Full agreement to be filed with Q3 2026 Form 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.